b'Flow Hematolymphoid Screening Panel -CytometryFlow CytometryClinical Information This panel not only provides evaluation and monitoring ofTest Name Indications for TestingThe 10-color Hematolymphoid Screening Panel provides apatients with hematological malignancy but provides a wideHematolymphoid Screening PanelClassifying Acute Leukemiacomprehensive approach for evaluating bone marrow andarray of applications due to its comprehensive biomarker peripheral blood samples for the presence or absence ofselection. Diagnosing and Classifying B cell Disorders Assay Type Evaluating T cell and NK disordershematolymphoid malignancies. The panel characterizes and identifies all major white blood cell lineages and identifiesBiomarkers in the Screening Panel Multiparametric Flow Cytometry (10-color) Evaluating Plasma Cell Dyscrasiasall major types of hematopoietic neoplasia. BiomarkerCD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, selection follows the 2006 Bethesda Consensus 1forCD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45,CAP/CLIA-validatedimmunophenotypic analysis of hematolymphoid neoplasiaCD56, CD57, CD64, CD71, CD117, CD123, HLA-DR, Kappa, with additions chosen by our internal hematopathologistLambda, and TCR Gamma/Delta. Method Descriptionbased on recent literature including the 2017 WHO Classification of Tumours of Haematopoietic and LymphoidImmunophenotyping-Lyse/Wash/StainTissues. 2-8 Interpretation TurnaroundSpecimenShippingSpecimen Time Requirements Conditions StabilityAn interpretive24-48 hours2-4 mL of bone marrow orAmbient or Cool; Specimensreport will beperipheral blood in EDTA orDo not freezeshould be stored issuedfor theSodium Heparin at 2-8C and interrogatedmust be received sample indicatingby the lab within presence/absence48 hours after of normal anddrawReferences abnormal cell populations and 1.BL Wood et al., Cytometry B Clin Cytom. 72:S14-S22 (2007). their associated 2.FE Craig et al., Blood. 111(8):3941-67 (2008).immunophenotypic profile. 3.BL Wood. Arch Pathol Lab Med. 130:680-90 (2006).4.SH Swerdlow et al., WHO Classification of Tumours, Revised 4th Edition, Volume 2 (2017) 5.CLSI H43: Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells, 2nd Edition6.JJ Van Dongen et al., Leukemia. 26(9):1908-75 (2012).7.A Porwit and A Rajab. Int. Jnl. Lab. Hem., 37:133-143 (2015).8.Sheikholeslami et al., Methods in Molecular Biology.378. 53-63. 10.1007/978-1-59745-323-3_4 (2007).58 LabPMM Services Catalog 2021|59'